A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma
Ramos, L.; Truong, S.; Zhai, B.; Joshi, J.; Ghaidi, F.; Lizardo, M. M.; Shyp, T.; Adomat, H.; LeBihan, S.; Collins, C. C.; Bacha, J.; Brown, D.; Langlands, J.; Shen, W.; Lallous, N.; Sorensen, P. H.; Daugaard, M.
Show abstract
HDAC inhibition has been shown to induce pharmacological BRCAness in cancer cells with proficient DNA repair activity. This provides a rationale for exploring combination treatments with HDAC and PARP inhibition in cancer types that are insensitive to single-agent PARP inhibitors. Here, we report the concept and characterization of a novel bifunctional PARP inhibitor (kt-3283) with dual activity towards PARP1/2 and HDAC enzymes in Ewing sarcoma cells. Compared to the FDA-approved PARP (olaparib) and HDAC (vorinostat) inhibitors, kt-3283 displayed enhanced cytotoxicity in Ewing sarcoma models. The kt-3283-induced cytotoxicity was associated with a strong S and G2/M cell cycle arrest in the nanomolar concentration range and elevated DNA damage as assessed by {gamma}H2AX tracking and comet assays. In three-dimensional spheroid models of Ewing sarcoma, kt-3283 showed efficacy in lower concentrations than olaparib and vorinostat and kt-3283 inhibited colonization of Ewing sarcoma cells in an ex vivo lung metastasis model. In summary, our data demonstrates the preclinical justification for studying the benefit of dual PARP and HDAC inhibition in the treatment of Ewing sarcoma in a clinical trial and provides proof-of-concept for a bi-functional single-molecule therapeutic strategy.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Inhibition of the Myocardin-Related Transcription Factor pathway increases efficacy of Trametinib in NRAS-mutant melanoma cell lines 96%
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 95%
- MCAK Inhibitors Induce Aneuploidy in Triple Negative Breast Cancer Models 94%
Similar papers in this journal
- Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 95%
- Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers 95%
- Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death 94%
Similar papers in this journal
- Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor 95%
- Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma 95%
- Altering mammalian transcription networking with ADAADi: An inhibitor of ATP-dependent chromatin remodeling 95%
Similar papers in this journal
- Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancers 95%
- p300 KAT regulates SOX10 stability and function in human melanoma 94%
- A kinome-wide synthetic lethal CRISPR/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4/CDK6 blockade in HNSCC 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.